https://www.zacks.com/stock/news/2244198/biotech-stock-roundup-gern-crnx-gain-on-updates-bmy-s-car-t-cell-therapy-news-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2244198
Mar 21, 2024 - Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.
zc:-3980058176579956040
0
https://seekingalpha.com/news/4081853-bristol-myers-gets-eu-approval-for-abecma-for-multiple-myeloma?source=feed_sector_healthcare
Mar 20, 2024 - Bristol Myers (BMY) has received EU regulatory approval for its CAR T-cell therapy Abecma in the treatment of relapsed or refractory multiple myeloma. Read more here.
0
sa:2295599855823458836
0
https://www.zacks.com/stock/news/2243567/is-it-wise-to-retain-sba-communications-sbac-stock-for-now?cid=CS-ZC-FT-analyst_blog|zer_report_update-2243567
Mar 20, 2024 - SBA Communications (SBAC) is likely to benefit from the rising global demand for wireless connectivity and its asset buyouts. However, notable customer concentration and high interest rates are key woes.
zc:-9028235653957723152
0
https://www.nrn.com/quick-service/subway-plans-four-sauces-grocery-sales
Mar 20, 2024 - Restaurant brand teams with T. Marzetti Co. for scholarship fund benefit
0
nrn:5140407115866064891
0
https://www.zacks.com/stock/news/2242974/5-reasons-to-invest-in-t-rowe-price-trow-stock-right-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2242974
Mar 19, 2024 - T. Rowe Price's (TROW) solid AUM balance, business diversification initiatives, acquisitions and global reach make it an attractive investment option.
zc:4301884081902904745
0
https://seekingalpha.com/news/4080447-citius-pharmaceuticals-receives-fda-acceptance-of-resubmission-for-its-relapsed-lymphoma-treatment?source=feed_sector_healthcare
Mar 18, 2024 - Citius Pharmaceuticals announces FDA acceptance of resubmission for LYMPHIR, a promising immunotherapy for cutaneous T-cell lymphoma treatment.
0
sa:-5122431861347180241
0
https://seekingalpha.com/article/4678703-poseida-april-2024-data-could-shed-light-on-differentiated-car-t-advancement?source=feed_all_articles
Mar 16, 2024 - Poseida is expected to release results from the phase 1 study using P-BCMA-ALLO1 on April 8th, 2024. Read why PSTX stock is a Buy.
0
sa:-4593629371493091987
0
https://seekingalpha.com/news/4080088-jj-wins-fda-adcom-carvykti-label-expansion?source=feed_sector_healthcare
Mar 15, 2024 - FDA advisors unanimously voted to expand labeling for Carvykti, a CAR-T therapy developed by J&J (JNJ) and Legend Biotech (LEGN), for multiple myeloma. Read more here.
0
sa:-5134546788001620226
0
https://www.fool.com/investing/2024/03/15/the-smartest-dividend-stocks-to-buy-with-400-right/?source=iedfolrf0000001
Mar 15, 2024 - It's time to reward yourself with companies that treat their shareholders with steady and growing payouts.
0
fool:4905277460120251
0
https://www.zacks.com/stock/news/2241446/bristol-myers-bmy-gets-fda-nod-for-breyanzi-s-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241446
Mar 15, 2024 - Bristol Myers (BMY) obtains FDA approval for the label expansion of CAR T cell therapy, Breyanzi, for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
zc:-3282508303580057856
0